Axovant Sciences Ltd (AXGT) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Axovant Sciences Ltd (NASDAQ:AXGT) have been given an average recommendation of “Buy” by the six ratings firms that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $5.05.

Several equities research analysts have commented on the stock. Evercore ISI assumed coverage on shares of Axovant Sciences in a research report on Thursday. They issued an “outperform” rating on the stock. Guggenheim assumed coverage on shares of Axovant Sciences in a research report on Friday, February 15th. They issued a “buy” rating and a $7.00 price target on the stock. Chardan Capital upgraded shares of Axovant Sciences from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Axovant Sciences in a research report on Tuesday, March 12th. Finally, Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Wednesday.

Axovant Sciences stock traded down $0.02 during midday trading on Thursday, hitting $1.07. The company’s stock had a trading volume of 1,232,309 shares, compared to its average volume of 2,423,234. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 1.24. Axovant Sciences has a 12 month low of $0.93 and a 12 month high of $6.59. The stock has a market cap of $177.34 million, a PE ratio of -0.52 and a beta of 1.33.

Axovant Sciences (NASDAQ:AXGT) last issued its quarterly earnings results on Thursday, February 7th. The company reported ($0.27) EPS for the quarter, hitting the consensus estimate of ($0.27). On average, equities analysts predict that Axovant Sciences will post -1.21 EPS for the current fiscal year.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics in the fields of neurology and psychiatry. Its therapeutic focus are Parkinson’s Disease and Lewy Body Dementia. It operates through the following geographical sgements: United States, Switzerland, Bermuda, and Other.

Recommended Story: Do Tariffs Work?

Analyst Recommendations for Axovant Sciences (NASDAQ:AXGT)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.